Stockreport
Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
TheFly reported on April 9 that Guggenheim increased its price target on AMGN from $347 to $351 while maintaining a Neutral rating on the stock. The firm noted that it is updating its financial model ahead of the company's first-quarter results, which are expected after market close on April 30. In a separate movement, on April 6, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for TEPEZZA delivered through a subcutaneous on-body injector in patients with moderate-to-severe active thyroid eye disease. The study achieved its primary endpoint, showing a 77% proptosis response rate compared with 19.6% for placebo over 24 weeks, with a mean eye bulge reduction of -3.17 mm versus -0.80 mm. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings The trial also met multiple secondary endpoints, including improvements in diplopia outcomes, disease activity scores, quality-of-life measures, and overall responder rates, with statisticall
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER [TheStreet.com][TheStreet.com]
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER[PR Newswire]
- USPTO Allows Antibody Genus Claims in Patent Enabled by Integral Molecular's Paratope-PLUS™ CDR-Scanning [Yahoo! Finance][Yahoo! Finance]
- What to Expect From Amgen's Next Quarterly Earnings Report [Yahoo! Finance][Yahoo! Finance]
- Amgen (AMGN) was given a new $366.00 price target by Canaccord Genuity Group Inc..[MarketBeat]
- More
AMGN
SEC Filings
SEC Filings
- 4/22/26 - Form 8-K
- 4/21/26 - Form DEFA14A
- 4/15/26 - Form DEFA14A
- AMGN's page on the SEC website
- More